Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients-Reference-Cited by-同舟云学术

Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients

Published:2024-06-15 Issue:7 Volume:11 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Ni Bin¹^ORCID,Wolfe Cameron R¹,Arif Sana¹,Carugati Manuela¹^ORCID,Heldman Madeleine R¹^ORCID,Messina Julia A¹^ORCID,Miller Rachel A¹,Saullo Jennifer L¹^ORCID,Baker Arthur W¹^ORCID,Maziarz Eileen K¹^ORCID

Affiliation:

1. Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina , USA

Abstract

Abstract We evaluated use of maribavir (MBV) for treatment of 15 episodes of refractory/resistant cytomegalovirus infection in 13 solid organ transplant recipients. Treatment failure due to treatment-emergent MBV resistance or early virological recurrence after MBV discontinuation occurred in 7 (47%) episodes. Sustained viral clearance was achieved in 6 (40%) episodes.

Funder

National Institute of Allergy and Infectious Diseases

National Institutes of Health

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofae335/58241185/ofae335.pdf

Reference13 articles.

1. Cytomegalovirus in solid organ transplant recipients—guidelines of the American Society of Transplantation Infectious Diseases Community of Practice;Razonable;Clin Transplant,2019

2. New insights on CMV management in solid organ transplant patients: prevention, treatment, and management of resistant/refractory disease;Kotton;Infect Dis Ther,2023

3. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study;Papanicolaou;Clin Infect Dis,2019

4. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial;Avery;Clin Infect Dis,2022

5. Maribavir for preemptive treatment of cytomegalovirus reactivation;Maertens;N Engl J Med,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maribavir treatment for resistant cytomegalovirus disseminated disease in kidney transplant recipients: A case-based scoping review of real life data in literature;Transplantation Reviews;2024-12